Catalog4 refs
Prostamax (KEDP)
Healing & RecoveryResearch use only
Educational use only. Not medical advice. Verify all information with primary sources and a licensed clinician before use.
Body Map
chromatincells
Overview
A Khavinson bioregulator tetrapeptide (KEDP) with primary repair effects on prostate tissue. Developed by Professor Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, it alters chromatin structure in cells from elderly individuals, promoting deheterochromatinization and potentially reactivating genes repressed during aging. Research in rat models shows reduced prostate inflammation, decreased swelling, and decelerated pathological remodeling associated with prostatitis.
Primary Uses
Reduces prostate inflammation
Decreases prostatic swelling
Reduces vascular congestion (hyperemia)
Decreases immune cell infiltration
Reduces scarring in prostate tissue
Promotes chromatin decondensation
Reactivates age-repressed genes
Improves lymphocyte function
Chronic prostatitis treatment
Prostatic inflammation mitigation
Prostate tissue repair
Chromatin remodeling
Gene reactivation
Lymphocyte function normalization
Protocol Reference
Dose
10-20 mg
Frequency
Daily for 10-20 days per cycle; maintenance: 2-3 cycles yearly
Half-life
Not established
Route
Oral capsules · Injectable
Evidence
Moderate Research
Research Models
HumanRat
Also in Healing & Recovery